Division of Gastroenterology, Hepatology, and NutritionDepartment of PediatricsUniversity of California San Diego School of MedicineLa JollaCA.
Division of GastroenterologyDepartment of PediatricsRady Children's HospitalSan DiegoCA.
Hepatology. 2021 Mar;73(3):937-951. doi: 10.1002/hep.31317. Epub 2020 Nov 30.
Predictive, noninvasive tools are needed to monitor key features of nonalcoholic fatty liver disease (NAFLD) in children that relate to improvement in liver histology. The purpose of this study was to evaluate the relationship between liver chemistries and liver histology using data from the CyNCh (Cysteamine Bitartrate Delayed-Release for the Treatment of NAFLD in Children) clinical trial.
This study included 146 children. Improvement in liver histology, defined as decrease in nonalcoholic fatty liver disease (NAFLD) Activity Score ≥2 points without worsening of fibrosis, occurred in 43 participants (30%). There were 46 participants with borderline zone 1 nonalcoholic steatohepatitis (NASH) at baseline, with resolution in 28% (12 of 46). Multivariate models were constructed using baseline and change in alanine aminotransferase (ALT), aspartate aminotransferase (AST), and gamma-glutamyl transferase (GGT) at 52 weeks, for improvement in (1) liver histology primary outcome, (2) borderline zone 1 NASH, and (3) fibrosis. For improvement in histology, the model (P < 0.0001) retained baseline and change in GGT (area under the receiver operating characteristic [AUROC], 0.79; 95% confidence interval [CI], 0.71-0.87). For borderline zone 1 NASH, the model (P = 0.0004) retained baseline and change in ALT (AUROC, 0.80; 95% CI, 0.67-0.93). For fibrosis, the model (P < 0.001) retained baseline and change in ALT (AUROC, 0.80; 95% CI, 0.67-0.93). Additional clinical parameters were added to the models using Akaike's information criterion selection, and significantly boosted performance: improvement in histology with AUROC of 0.89 (95% CI, 0.82-0.95), borderline zone 1 NASH with AUROC of 0.91 (95% CI, 0.83-0.99), and fibrosis with AUROC of 0.89 (95% CI, 0.82-0.94). Models were validated using data from the TONIC (Treatment of Nonalcoholic Fatty Liver Disease in Children) trial.
In children with NAFLD, dynamic changes in serum ALT and GGT are associated with change in liver histology and appear to be powerful indicators of histological response.
需要预测性、非侵入性的工具来监测与肝组织学改善相关的非酒精性脂肪性肝病(NAFLD)的关键特征。本研究的目的是使用 CyNCh(用于治疗儿童非酒精性脂肪性肝病的半胱胺盐酸盐延迟释放)临床试验的数据来评估肝化学与肝组织学之间的关系。
本研究纳入了 146 名儿童。43 名参与者(30%)的肝组织学改善定义为非酒精性脂肪性肝病(NAFLD)活动评分至少降低 2 分,且纤维化无恶化。基线时有 46 名参与者存在边界区 1 型非酒精性脂肪性肝炎(NASH),其中 28%(12/46)得到缓解。使用基线时和 52 周时丙氨酸氨基转移酶(ALT)、天冬氨酸氨基转移酶(AST)和γ-谷氨酰转移酶(GGT)的变化,构建了用于改善(1)肝组织学主要结局、(2)边界区 1 NASH 和(3)纤维化的多变量模型。对于组织学改善,该模型(P<0.0001)保留了基线和 GGT 的变化(接受者操作特征曲线下面积[AUROC],0.79;95%置信区间[CI],0.71-0.87)。对于边界区 1 NASH,该模型(P=0.0004)保留了基线和 ALT 的变化(AUROC,0.80;95%CI,0.67-0.93)。对于纤维化,该模型(P<0.001)保留了基线和 ALT 的变化(AUROC,0.80;95%CI,0.67-0.93)。使用赤池信息量准则选择向模型中添加了其他临床参数,显著提高了性能:组织学改善的 AUROC 为 0.89(95%CI,0.82-0.95),边界区 1 NASH 的 AUROC 为 0.91(95%CI,0.83-0.99),纤维化的 AUROC 为 0.89(95%CI,0.82-0.94)。使用 TONIC(治疗儿童非酒精性脂肪性肝病)试验的数据对模型进行了验证。
在患有 NAFLD 的儿童中,血清 ALT 和 GGT 的动态变化与肝组织学变化相关,似乎是组织学反应的有力指标。